Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Ovarian Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Adnexal Neoplasm
Female Reproductive System Adnexal Neoplasm
Ovarian Neoplasm

Subtype

Ovarian Neoplasm

CI-CAN-00001335Explore in graph →

Non-malignant746 active trials5 approved drugs94 evidence items

NCIt: C4984
MeSH: D010051

Overview
Statistics
Survival
Genomics9
Variants & evidence94
Drugs32
Trials3430
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (174)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 174 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
· Cancer Discov · 2017 · PMID 28242752 · validated civic_curation pubmed
A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors.
· Mod Pathol · 2015 · PMID 26428316 · validated civic_curation pubmed
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed
CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
· Cancer Sci · 2015 · PMID 26250934 · validated civic_curation pubmed
Aurora kinases as prognostic biomarkers in ovarian carcinoma.
· Hum Pathol · 2009 · PMID 19157502 · validated civic_curation pubmed
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
· JAMA · 2012 · PMID 22274685 · validated civic_curation pubmed
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
· Oncogene · 2012 · PMID 22139083 · validated civic_curation

Showing 126–150 of 174 publications

← Previous
1
…
5
6
7
Next →

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

· Gynecol Oncol · 2012 · PMID 22112610 · validated civic_curation pubmed

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

· Clin Cancer Res · 2006 · PMID 16467099 · validated civic_curation pubmed

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

· Gynecol Oncol · 2011 · PMID 21920589 · validated civic_curation pubmed

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

· Clin Cancer Res · 2014 · PMID 24240112 · validated civic_curation pubmed

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

· Gynecol Oncol · 2016 · PMID 26740259 · validated civic_curation pubmed

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

· Lancet Oncol · 2014 · PMID 25218906 · validated civic_curation pubmed

The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.

· PLoS One · 2015 · PMID 26422378 · validated civic_curation pubmed

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation pubmed

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2017 · PMID 27908594 · validated civic_curation pubmed

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

· N Engl J Med · 2012 · PMID 22187960 · validated civic_curation pubmed

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

· J Clin Oncol · 2020 · PMID 32822286 · validated civic_curation pubmed

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

· Gynecol Oncol · 2019 · PMID 30797591 · validated civic_curation pubmed

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

· Br J Clin Pharmacol · 2015 · PMID 26033044 · validated civic_curation pubmed

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

· Bone Marrow Transplant · 2010 · PMID 19648970 · validated civic_curation pubmed

A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.

· Oncol Lett · 2013 · PMID 24137399 · validated civic_curation pubmed

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed